CHARM Therapeutics, Co-Founded by Nobel Laureate David Baker, Secures $80M Series B to Advance Next-Gen Menin Inhibitor for AML

Sep 03, 2025 22:02 CST Updated 22:02

CHARM Therapeutics

Small Molecule Drug Developer

↑↑↑ Long press or scan the code to register for the conference ↑↑↑

9Month2Day, by Nobel laureateDavid BakerCo-foundedCHARM TherapeuticsAnnouncement Completed8000Million USD Over-subscriptionBRound of financing. This round of financing was led byNew Enterprise AssociateAndSR OneCo-led by, existing investorsOrbiMed、F-Prime、Khosla VenturesAndNVIDIAFollow-on investment. The proceeds will be used to advance the next generationmeninClinical Development of Inhibitors.

Acute Myeloid Leukemia (AML) is an aggressive blood cancer with rapid progression, and many patients have a poor prognosis.AMLA key driver ismeninAndKMT2AProtein between-Protein Interactions,KMT2ACoding Lysine Methyltransferase2A. In normal cells,KMT2AHelps control transcription and differentiation. However, in someAMLSubtype,meninAndKMT2AThe combination drives the upregulation of genes that directly promote the formation and maintenance of leukemia cells.

MeninInhibitors are clinically validatedAMLTherapeutic Drugs(The world's firstmeninInhibitorrevumenibIn2024Year11Month15Daily HarvestFDAApproved for Marketing), by restoring normal gene regulation and triggering the differentiation or death of cancer cells. However, the first-generation therapies are limited bymeninThe limitation of rapid emergence of drug-resistant mutations in proteins, which reduces efficacy and leads to recurrence and disease progression. Additionally, some first-generationmeninThe efficacy of inhibitors may be limited by safety risks, such asQTcProlonged, poor drug properties (e.g., drugs-The possibility of drug interactions) and the need for high therapeutic doses.

As the development of a new generationmeninPioneer of Inhibitors,Using a proprietary protein-ligand co-folding platformDragonFold, CHARM has identified a development candidate that maintains efficacy against all publicly described clinical resistance mutations. In preclinical models, this candidate drug led to robust tumor regression. The molecule is expected to be effective at low doses in humans. Based onAIHigh-quality molecules designed,CHARMAiming toAMLPatients are provided with more effective, longer-lasting, and safer options.meninInhibitor.

Co-founder of CHARM Therapeutics (Source: Company website)

CHARMFounded in2021Year, dedicated to leveraging its proprietaryAIDriving drug discovery platforms to pioneer the next generation of precision oncology treatments. To date, the company has raised over1.5Billion US dollars.

"Our Candidate for the Next GenerationmeninInhibitors Represent ChangeAML"An important opportunity for patients' prognosis, the company looks forward to initiating clinical development early next year."CHARMCEOGary D. GlickDr. said.

References:

[1]https://charmtx.com/charm-therapeutics-raises-80-million-in-series-b-financing-to-advance-development-of-best-in-class-menin-inhibitor-for-aml/

[2]https://corserahealth.com/news

[3]https://www.prnewswire.com/news-releases/syndax-announces-fda-approval-of-revuforj-revumenib-the-first-and-only-menin-inhibitor-to-treat-adult-and-pediatric-patients-with-relapsed-or-refractory-acute-leukemia-with-a-kmt2a-translocation-302307513.html

September 24th-25th, Beijing,2025 China Pharmaceutical Decision-Makers SummitWillBased on the development achievements and experiential insights of China's innovative drug industry over the past decade, and combining with the current industry bottlenecks and atmosphere, this discussion explores the trends and breakthroughs for the industry in the next 10 years. It focuses on representative scenarios such as the return on investment in China’s innovative drugs, the growth and advancement of Biotech, commercialization challenges and opportunities, and international expansion.

——Welcome to scan the QR code for free registration——

Copyright © 2025 PHARMCUBE. All Rights Reserved. Disclaimer: The information in this WeChat article is for general reference only and should not be used directly as decision-making content. Pharmcube is not responsible for any loss incurred by any party due to the use of the content herein.